Premier Alternatives

KaloCyte

Biotechnology · Baltimore, MD · Privately Held (backing)

Developer of a red blood cell substitute designed to support oxygen delivery in trauma care settings. KaloCyte is based in Baltimore, MD. It was valued at $24.7 million at its later-stage round in Jun 2025, the last priced event on record. It has raised $5.7 million across 1 recorded round; the latest was an accelerator round in Jan 2020.

PMV mark · valuation
$24.7M
Oct 2026
Priced at
its later-stage round
Jun 2025
Total raised
$5.7M
Last round
Accelerator/Incubator
Jan 2020

KaloCyte key facts

as of Oct 2026
  • Developer of a red blood cell substitute designed to support oxygen delivery in trauma care settings.
  • KaloCyte is valued at approximately $24.7M as of Oct 2026, set at its later-stage round, Jun 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $5.7M across 1 recorded rounds; the latest was Accelerator/Incubator in Jan 2020.
  • Notable investors include Springboard Enterprises, United States Department of War, TEDCO, Johnson & Johnson Innovation - JLABS, BioGenerator Ventures — 21 tracked in total.
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$24.7M

Valued at $24.7M at its later-stage round, Jun 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of KaloCyte with a free account
  • ·The complete investor list: 21 names
  • ·Watch KaloCyte: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

KaloCyte funding rounds

1 rounds
Jan 2020Accelerator/Incubator—▮
Full funding history →

KaloCyte valuation

KaloCyte was valued at $24.7 million at its later-stage round in Jun 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has KaloCyte raised?

KaloCyte has raised $5.7 million in total; 1 of its rounds is on record. The most recent was an accelerator round in Jan 2020.

KaloCyte investors

21 investors are on record for KaloCyte, including Springboard Enterprises, United States Department of War, TEDCO and Johnson & Johnson Innovation - JLABS.

Comparable companies

Comparable biotechnology names by valuation on PrivateMarketView: Azalea Therapeutics ($153 million), Industrial Microbes ($24 million) and Kano Therapeutics ($15 million).

About KaloCyte

Developer of a red blood cell substitute designed to support oxygen delivery in trauma care settings. The company offers context-dependent oxygen release with reduced vasoconstriction and minimized methemoglobin formation, enabling emergency physicians, military medical teams, and critical care providers to treat traumatic hemorrhage when banked blood is unavailable or unsuitable.

Industry
Biotechnology
Sector
Healthcare
HQ
Baltimore, MD, United States
Employees
12
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.